GSK raises 2024 profit forecast but says sales growth to slow in 2nd half
By Eva Mathews (Reuters) -GSK raised its full-year profit forecast on Wednesday on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. CEO Emma Walmsley’s strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. …
GSK raises 2024 profit forecast but says sales growth to slow in 2nd half Read More »










